{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:02:20Z","timestamp":1776337340789,"version":"3.51.2"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"JSPS KAKENHI","award":["17K01969"],"award-info":[{"award-number":["17K01969"]}]},{"name":"JSPS KAKENHI","award":["16K10195"],"award-info":[{"award-number":["16K10195"]}]},{"name":"JSPS KAKENHI","award":["17H07222"],"award-info":[{"award-number":["17H07222"]}]},{"name":"JSPS KAKENHI","award":["17H04252"],"award-info":[{"award-number":["17H04252"]}]},{"name":"JSPS KAKENHI","award":["15H03086"],"award-info":[{"award-number":["15H03086"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.neuint.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T02:10:30Z","timestamp":1549332630000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia"],"prefix":"10.1016","volume":"125","author":[{"given":"Hidetsugu","family":"Fujigaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Nabeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2019.02.001_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(95)91325-4","article-title":"Symptoms, signs, and diagnosis of schizophrenia","volume":"346","author":"Andreasen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2019.02.001_bib2","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1460-9568.2008.06077.x","article-title":"Allosteric modulation of alpha 7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous gabaergic transmission","volume":"27","author":"Arnaiz-Cot","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2019.02.001_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0733-8627(20)30258-3","article-title":"Phencyclidine","volume":"8","author":"Baldridge","year":"1990","journal-title":"Emerg. Med. Clin. N. Am."},{"key":"10.1016\/j.neuint.2019.02.001_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.gene.2007.04.010","article-title":"Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice","volume":"396","author":"Ball","year":"2007","journal-title":"Gene"},{"key":"10.1016\/j.neuint.2019.02.001_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.biocel.2008.01.005","article-title":"Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway","volume":"41","author":"Ball","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.neuint.2019.02.001_bib6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1042\/bj2680437","article-title":"Glutamine synthesis from aspartate in Guinea-pig renal cortex","volume":"268","author":"Baverel","year":"1990","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuint.2019.02.001_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/321168a0","article-title":"Replication of the neurochemical characteristics of huntington's disease by quinolinic acid","volume":"321","author":"Beal","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2019.02.001_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/1056-8719(95)00028-G","article-title":"On the true affinity of glycine for its binding site at the nmda receptor complex","volume":"34","author":"Berger","year":"1995","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.neuint.2019.02.001_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(88)90814-X","article-title":"Kynurenate and fg9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors","volume":"151","author":"Birch","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0014-2999(88)90367-6","article-title":"Kynurenic acid antagonises responses to nmda via an action at the strychnine-insensitive glycine receptor","volume":"154","author":"Birch","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib11","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.3390\/ijms16059772","article-title":"Changing the face of kynurenines and neurotoxicity: therapeutic considerations","volume":"16","author":"Bohar","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2019.02.001_bib12","series-title":"Emergency Department Visits Involving Phencyclidine (Pcp)","first-page":"1","author":"Bush","year":"2013"},{"key":"10.1016\/j.neuint.2019.02.001_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bbr.2009.03.013","article-title":"L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning","volume":"201","author":"Chess","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuint.2019.02.001_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/schbul\/sbl033","article-title":"Elevations of endogenous kynurenic acid produce spatial working memory deficits","volume":"33","author":"Chess","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuint.2019.02.001_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neulet.2008.06.007","article-title":"Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for ifn-gamma?","volume":"441","author":"Connor","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuint.2019.02.001_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041108","article-title":"Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons","volume":"7","author":"Dobelis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuint.2019.02.001_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0304-3940(01)02242-X","article-title":"Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia","volume":"313","author":"Erhardt","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuint.2019.02.001_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.biopsych.2016.12.011","article-title":"Adaptive and behavioral changes in kynurenine 3-monooxygenase knockout mice: relevance to psychotic disorders","volume":"82","author":"Erhardt","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2019.02.001_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2004.06.006","article-title":"Endogenous kynurenic acid disrupts prepulse inhibition","volume":"56","author":"Erhardt","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2019.02.001_bib20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jb\/mvj072","volume":"139","author":"Fujigaki","year":"2006","journal-title":"J. Biochem."},{"key":"10.1016\/j.neuint.2019.02.001_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.neuropharm.2016.01.011","article-title":"L-tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences","volume":"112","author":"Fujigaki","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2019.02.001_bib22","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.neuropharm.2011.03.015","article-title":"Nmda receptors, cognition and schizophrenia--testing the validity of the nmda receptor hypofunction hypothesis","volume":"62","author":"Gilmour","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2019.02.001_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00213-008-1271-z","article-title":"Pharmacological stimulation of nmda receptors via co-agonist site suppresses fmri response to phencyclidine in the rat","volume":"201","author":"Gozzi","year":"2008","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuint.2019.02.001_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \"right stuff\"?","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuint.2019.02.001_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/npp.2014.207","article-title":"Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving d(3)-5-ht(2)a and d(1)-nmda receptors in the mpfc","volume":"40","author":"Hida","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuint.2019.02.001_bib26","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2019.02.001_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0074-7742(06)78003-5","article-title":"Glutamate and schizophrenia: phencyclidine, n-methyl-d-aspartate receptors, and dopamine-glutamate interactions","volume":"78","author":"Javitt","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuint.2019.02.001_bib28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuint.2019.02.001_bib29","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/schbul\/sbs069","article-title":"Has an angel shown the way? Etiological and therapeutic implications of the pcp\/nmda model of schizophrenia","volume":"38","author":"Javitt","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuint.2019.02.001_bib30","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.2174\/0929867322666150608094054","article-title":"Kynurenine aminotransferases and the prospects of inhibitors for the treatment of schizophrenia","volume":"22","author":"Jayawickrama","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuint.2019.02.001_bib31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/(SICI)1097-4547(19980615)52:6<709::AID-JNR10>3.0.CO;2-U","article-title":"Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex","volume":"52","author":"Johnson","year":"1998","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuint.2019.02.001_bib32","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib33","series-title":"Phencyclidine (Pcp) Toxicity, Statpearls, Treasure Island (FL)","author":"Journey","year":"2018"},{"key":"10.1016\/j.neuint.2019.02.001_bib34","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1471-4159.1989.tb01881.x","article-title":"A glycine site associated with n-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists","volume":"52","author":"Kessler","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuint.2019.02.001_bib35","doi-asserted-by":"crossref","first-page":"10592","DOI":"10.1523\/JNEUROSCI.1107-14.2014","article-title":"Reduction of brain kynurenic acid improves cognitive function","volume":"34","author":"Kozak","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2019.02.001_bib36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.neuropharm.2016.03.024","article-title":"Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases","volume":"112","author":"Lovelace","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2019.02.001_bib37","first-page":"3","article-title":"Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease","volume":"67","author":"Majewski","year":"2016","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0022-3956(74)90081-8","article-title":"Dopamine and the pharmacology of schizophrenia: the state of the evidence","volume":"11","author":"Matthysse","year":"1974","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuint.2019.02.001_bib39","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1158\/0008-5472.CAN-07-1872","article-title":"Novel tryptophan catabolic enzyme Ido2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound d-1-methyl-tryptophan","volume":"67","author":"Metz","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuint.2019.02.001_bib40","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nbd.2003.12.015","article-title":"Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia","volume":"15","author":"Miller","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2019.02.001_bib41","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/schbul\/sbs075","article-title":"Capturing the angel in \"angel dust\": twenty years of translational neuroscience studies of nmda receptor antagonists in animals and humans","volume":"38","author":"Moghaddam","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuint.2019.02.001_bib42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2009.06.003","article-title":"Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels","volume":"57","author":"Mok","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2019.02.001_bib43","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1017\/S146114571100085X","article-title":"Mouse strain differences in phencyclidine-induced behavioural changes","volume":"15","author":"Mouri","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neuint.2007.06.019","article-title":"Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment","volume":"51","author":"Mouri","year":"2007","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2019.02.001_bib45","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1196\/annals.1377.003","article-title":"Animal model of schizophrenia: dysfunction of nmda receptor-signaling in mice following withdrawal from repeated administration of phencyclidine","volume":"1086","author":"Nabeshima","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuint.2019.02.001_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060946","article-title":"Kynurenine aminotransferase isozyme inhibitors: a review","volume":"17","author":"Nematollahi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2019.02.001_bib47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0893-133X(00)00192-5","article-title":"Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors","volume":"24","author":"Noda","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuint.2019.02.001_bib48","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1476-5381.1995.tb15106.x","article-title":"Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia","volume":"116","author":"Noda","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib49","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0006-8993(82)91048-4","article-title":"An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid","volume":"247","author":"Perkins","year":"1982","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2019.02.001_bib50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neulet.2006.03.051","article-title":"Kynurenic acid has a dual action on ampa receptor responses","volume":"402","author":"Prescott","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuint.2019.02.001_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00001756-200101220-00010","article-title":"Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment","volume":"12","author":"Qiao","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuint.2019.02.001_bib52","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1176\/ajp.132.10.1076","article-title":"Prolonged psychosis attributed to phencyclidine: report of three cases","volume":"132","author":"Rainey","year":"1975","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuint.2019.02.001_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0922-4106(89)90040-0","article-title":"Nmda receptor antagonists that bind to the strychnine-insensitive glycine site and inhibit nmda-induced ca2+ fluxes and [3h]gaba release","volume":"172","author":"Reynolds","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059334","article-title":"The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate nmda receptor","volume":"8","author":"Roth","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuint.2019.02.001_bib55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-8993(91)91171-V","article-title":"Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of c57bl6 mice","volume":"546","author":"Saito","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2019.02.001_bib56","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1111\/j.1471-4159.1993.tb07443.x","article-title":"Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation","volume":"61","author":"Saito","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuint.2019.02.001_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0165-0270(94)00173-E","article-title":"Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment","volume":"59","author":"Sams-Dodd","year":"1995","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuint.2019.02.001_bib58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrn3257","article-title":"Kynurenines in the mammalian brain: when physiology meets pathology","volume":"13","author":"Schwarcz","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuint.2019.02.001_bib59","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0006-3223(01)01078-2","article-title":"Increased cortical kynurenate content in schizophrenia","volume":"50","author":"Schwarcz","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2019.02.001_bib60","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.6849138","article-title":"Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain","volume":"219","author":"Schwarcz","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuint.2019.02.001_bib61","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/S0021-9258(17)30447-7","article-title":"Indoleamine 2,3-dioxygenase. Purification and some properties","volume":"253","author":"Shimizu","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuint.2019.02.001_bib62","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0031-6997(25)00441-7","article-title":"Neuropharmacology of quinolinic and kynurenic acids","volume":"45","author":"Stone","year":"1993","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuint.2019.02.001_bib63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0165-6147(00)01451-6","article-title":"Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection","volume":"21","author":"Stone","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuint.2019.02.001_bib64","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1111\/j.1460-9568.2007.05540.x","article-title":"Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats","volume":"25","author":"Stone","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2019.02.001_bib65","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrd870","article-title":"Endogenous kynurenines as targets for drug discovery and development","volume":"1","author":"Stone","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuint.2019.02.001_bib66","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/bph.12230","article-title":"The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders","volume":"169","author":"Stone","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib67","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(81)90587-2","article-title":"Quinolinic acid: a potent endogenous excitant at amino acid receptors in cns","volume":"72","author":"Stone","year":"1981","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib68","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-2999(79)90279-6","article-title":"Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats","volume":"59","author":"Sturgeon","year":"1979","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.02.001_bib69","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1523\/JNEUROSCI.10-09-02965.1990","article-title":"Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors","volume":"10","author":"Swartz","year":"1990","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2019.02.001_bib70","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2174\/1568026611209061797","article-title":"Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction","volume":"12","author":"Szalardy","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuint.2019.02.001_bib71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbrc.2005.09.032","article-title":"Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism","volume":"338","author":"Takikawa","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuint.2019.02.001_bib72","doi-asserted-by":"crossref","first-page":"14116","DOI":"10.1523\/JNEUROSCI.2786-11.2011","article-title":"Gabaergic precursor transplantation into the prefrontal cortex prevents phencyclidine-induced cognitive deficits","volume":"31","author":"Tanaka","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2019.02.001_bib73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbr.2016.09.050","article-title":"Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions","volume":"317","author":"Tashiro","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuint.2019.02.001_bib74","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0197-0186(01)00133-4","article-title":"Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes","volume":"40","author":"Tavares","year":"2002","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2019.02.001_bib75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00001756-200002070-00005","article-title":"Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain","volume":"11","author":"Tavares","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuint.2019.02.001_bib76","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.brainresbull.2015.02.001","article-title":"The inimitable kynurenic acid: the roles of different ionotropic receptors in the action of kynurenic acid at a spinal level","volume":"112","author":"Tuboly","year":"2015","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuint.2019.02.001_bib77","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.neuropharm.2006.12.007","article-title":"Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model","volume":"52","author":"Wang","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2019.02.001_bib78","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrn1647","article-title":"The role of calmodulin as a signal integrator for synaptic plasticity","volume":"6","author":"Xia","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuint.2019.02.001_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081689","article-title":"New targets for schizophrenia treatment beyond the dopamine hypothesis","volume":"18","author":"Yang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2019.02.001_bib80","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.str.2018.05.004","article-title":"Glutamate and glycine binding to the nmda receptor","volume":"26","author":"Yu","year":"2018","journal-title":"Structure"}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018618305850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018618305850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:43:50Z","timestamp":1759311830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018618305850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":80,"alternative-id":["S0197018618305850"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2019.02.001","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}